International Patent: REMIBRUTINIB DRUG SUBSTANCE AND DRUG PRODUCT SUBSTANTIALLY FREE OF EPOXIDE IMPURITY

GENEVA, Sept. 18 -- NOVARTIS AG filed a patent application (IB2026/052090) for “REMIBRUTINIB DRUG SUBSTANCE AND DRUG PRODUCT SUBSTANTIALLY FREE OF EPOXIDE IMPURITY”. With publication no. WO/2026/185762, here are the other details related to the patent application:

Kind: Initial Publication without ISR [A2]

IPC: A61K 9/16

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....